The Alzheimer’s Deception: How Billions Were Wasted Chasing a False Cure

For decades, Alzheimer’s disease has been framed as a mysterious plague of the modern age—a tragic condition caused by sticky plaques called amyloids building up in the brain. Nearly all Alzheimer’s research, drug development, and funding have revolved around eliminating these plaques. Yet despite billions of dollars and decades of effort, this theory has failed to deliver meaningful treatments.

The amyloid hypothesis was once treated as gospel. It promised that clearing amyloids would restore memory and reverse dementia. But as time passed, it became clear that the foundation of this hypothesis rested on fraudulent or deeply flawed research, and that amyloid buildup was more likely a symptom than a cause of brain degeneration. Despite this, the pharmaceutical industry, the FDA, and academic medicine have doubled down on this failed approach—largely because it’s patentable and profitable.

The Billion-Dollar Alzheimer’s Drug Mirage

The first wave of so-called “breakthrough” Alzheimer’s drugs were monoclonal antibodies—laboratory-engineered molecules designed to attack amyloid proteins. The FDA granted accelerated approval to these drugs amid enormous controversy.

The first drug was priced at $56,000 per year, which would have bankrupted Medicare if widely prescribed. The FDA’s own independent advisory panel voted 10–0 against its approval, yet the agency pushed it through anyway. Three members of the panel resigned in protest, calling it “probably the worst drug approval decision in recent U.S. history.”

The clinical results were abysmal. The drug did not improve cognitive function—it only appeared to slow decline by a mere 20%, a difference so small that it likely reflected statistical noise rather than real benefit. Worse, 41% of patients suffered brain bleeding or swelling, along with headaches, confusion, and even delirium.

Subsequent monoclonal antibodies were slightly “better” on paper but remained devastatingly harmful. One caused brain swelling in 21% of users, another in 36.8%. Their claimed benefits—a 26% slowing of disease progression—translated to a 0.45-point improvement on a clinical scale, where 1–2 points are needed to make a real difference in daily life. In plain English, they did nothing patients could feel, yet exposed them to life-threatening risks.

Corruption at the Core

What makes this saga even more troubling is the role of financial conflict and regulatory capture. Every year, J.P. Morgan Chase hosts a private pharmaceutical investment conference that sets the tone for the drug industry. In 2023, the event’s highlights were the profits from the new Alzheimer’s drugs and GLP-1 weight-loss injectables like Ozempic.

The keynote speaker? The FDA Commissioner, whose agency had just pushed through another backdoor approval of an amyloid drug days before the conference. When the British Medical Journal investigated, they discovered that nine out of ten FDA advisory members who voted for one of these drugs had significant financial ties to the industry. The tenth “patient representative” couldn’t be traced at all.

The result? A carousel of approvals for drugs that didn’t work, driven by profit rather than patient benefit. Unsurprisingly, after a brief wave of hype, the market recognised the truth: the first drug’s price was halved, then it was withdrawn due to lack of sales. It generated only about $5 million—a rounding error for the industry. The others have sold modestly, around $295 million, despite heavy marketing.

The Real Damage: Science and Patients Betrayed

These failures reveal a deeper problem. The repeated brain damage caused by amyloid-targeting drugs suggests that amyloid might actually serve a protective function in the brain. Some evidence indicates that amyloid may patch blood vessel walls or neutralise toxins. Removing it may therefore harm, not heal.

The insistence on chasing amyloid reflects the medical system’s obsession with patentable solutions, even when non-patentable therapies show far more promise. The billions wasted on these drugs could have supported research into safer, cheaper, and more effective strategies for brain health.

What Actually Works: The Ignored Alternatives

When independent researchers and clinicians look beyond the pharmaceutical bubble, they find remarkable results from simple, affordable interventions.

One striking example is coconut oil and medium-chain triglycerides (MCTs). These compounds provide ketones—an alternative energy source for the brain that bypasses glucose metabolism, which is often impaired in Alzheimer’s.

A randomised controlled trial found that over six months, 80% of patients remained stable or improved using MCTs. That’s better than any amyloid drug trial ever achieved—and without the catastrophic side effects. The cost? Pennies per day, compared to the $30,000+ annual cost of monoclonal antibodies.

This is not to claim coconut oil “cures” dementia, but it shows how simple metabolic support can outperform billion-dollar pharmaceuticals. It also raises a damning question: why is the system so eager to promote toxic, marginally effective drugs while ignoring safe, accessible treatments?

A Paradigm Shift Waiting to Happen

The truth is that Alzheimer’s is not a one-cause, one-solution disease. It’s a complex metabolic and inflammatory condition involving mitochondrial dysfunction, vascular damage, insulin resistance, and environmental toxins. Amyloid plaques may be a downstream effect—or even part of the brain’s defence mechanism.

Real progress will only come when we abandon the pharmaceutical fixation on single targets and instead focus on restoring brain metabolism, circulation, and detoxification.

Promising directions include:

• Nutritional ketosis and MCT supplementation

• Anti-inflammatory diets rich in omega-3s, polyphenols, and antioxidants

• Targeting mitochondrial health with compounds like CoQ10, PQQ, and nicotinamide riboside

• Enhancing cerebral blood flow through lifestyle, oxygen therapies, or low-level light therapy

• Addressing root causes such as heavy metal exposure, infections, and systemic inflammation

Each of these approaches has a stronger physiological rationale and far better safety record than the amyloid antibody drugs.

Those are the solutions that we recommend too and include Red Light Therapy, Hyperbaric Oxygen Therapy, diet changes, Sanki Postbiotics

Sanki Postbiotics

and our Red Light Helmet.

Red Light Helmet

The Industry’s Cognitive Dissonance

Despite the evidence, institutions remain locked in their old paradigm. Drug companies cannot patent coconut oil or diet changes, so they have no financial incentive to explore them. Regulators and academic researchers, heavily funded by the same corporations, follow the money.

The public narrative continues to celebrate “breakthroughs” that are anything but. Media headlines trumpet each new drug approval while ignoring the underlying scandal: the suppression of cheap, effective, and safe alternatives.

The tragedy is not only scientific—it’s human. Millions of families live with the devastation of dementia, clinging to hope that medicine will finally deliver a real treatment. Instead, they are handed false promises and financial exploitation.

A Call for Sanity and Integrity

The Alzheimer’s crisis illustrates a broader truth about modern medicine: when profit dictates research priorities, patients lose and science regresses. It’s time to end the cycle of hype, harm, and disappointment.

We must redirect focus toward open, ethical, and patient-centred research—the kind that values human well-being over shareholder dividends. Alzheimer’s may not have a single cure, but genuine progress will only come from honest science and holistic understanding.

Until then, the best hope lies not in another billion-dollar drug but in reclaiming the wisdom of biology itself—supporting the brain’s natural resilience through nourishment, protection, and restoration.

Based on an article from 'A Midwestern Doctor' on Substack

Red Light Therapy